Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 An interaction between carbamazepine and fluvoxamine.

Literature DB >> 12959283

An interaction between carbamazepine and fluvoxamine.

V Martinelli, A Bocchetta, A M Palmas, M Del Zompo.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 1993 PMID： 12959283 PMCID： PMC1364671 DOI： 10.1111/j.1365-2125.1993.tb00425.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

12 in total

1. Inhibitors of imipramine metabolism by human liver microsomes.

Authors: E Skjelbo; K Brøsen
Journal: Br J Clin Pharmacol Date: 1992-09 Impact factor: 4.335

Review 2. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Authors: P Benfield; A Ward
Journal: Drugs Date: 1986-10 Impact factor: 9.546

3. Fluvoxamine-tricyclic antidepressant interaction. An accidental finding.

Authors: G Bertschy; S Vandel; B Vandel; G Allers; R Volmat
Journal: Eur J Clin Pharmacol Date: 1991 Impact factor: 2.953

4. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro.

Authors: M Pirmohamed; N R Kitteringham; T M Guenthner; A M Breckenridge; B K Park
Journal: Biochem Pharmacol Date: 1992-04-15 Impact factor: 5.858

5. Interaction of fluoxetine with carbamazepine.

Authors: H J Pearson
Journal: J Clin Psychiatry Date: 1990-03 Impact factor: 4.384

6. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up.

Authors: R M Post; G S Leverich; A S Rosoff; L L Altshuler
Journal: J Clin Psychopharmacol Date: 1990-10 Impact factor: 3.153

7. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

Authors: H K Crewe; M S Lennard; G T Tucker; F R Woods; R E Haddock
Journal: Br J Clin Pharmacol Date: 1992-09 Impact factor: 4.335

8. Fluvoxamine is a potent inhibitor of cytochrome P4501A2.

Authors: K Brøsen; E Skjelbo; B B Rasmussen; H E Poulsen; S Loft
Journal: Biochem Pharmacol Date: 1993-03-24 Impact factor: 5.858

9. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy.

Authors: A D Sperber
Journal: Drug Saf Date: 1991 Nov-Dec Impact factor: 5.606

10. Fluvoxamine, a new antidepressant drug, fails to show antiserotonin activity.

Authors: J Maj; Z Rogóz; G Skuza
Journal: Eur J Pharmacol Date: 1982-07-09 Impact factor: 4.432

8 in total

Review 1. Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors: P Loiseau
Journal: Drug Saf Date: 1998-12 Impact factor: 5.606

Review 2. Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors: J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal: Forensic Sci Med Pathol Date: 2010-11-04 Impact factor: 2.007

An interaction between carbamazepine and fluvoxamine.

1. Inhibitors of imipramine metabolism by human liver microsomes.

Review 2. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

3. Fluvoxamine-tricyclic antidepressant interaction. An accidental finding.

4. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro.

5. Interaction of fluoxetine with carbamazepine.

6. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up.

7. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

8. Fluvoxamine is a potent inhibitor of cytochrome P4501A2.

9. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy.

10. Fluvoxamine, a new antidepressant drug, fails to show antiserotonin activity.

Review 1. Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Review 2. Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Review 3. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Review 4. Clinically significant drug interactions with antidepressants in the elderly.

5. Deaths involving contraindicated and inappropriate combinations of serotonergic drugs.

Review 6. Fluvoxamine. A review of global drug-drug interaction data.

Review 7. Clinical pharmacokinetics of fluvoxamine.

Review 8. Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children.